A recent study offers a fresh perspective on pain by applying the lens of complexity science to chronic pain. We review the study's key points and discuss how psychedelic therapies may offer promising solutions.

Explore the role of the therapeutic alliance between patients and intervention facilitators in PAT for MDD; a stronger therapeutic alliance was associated with more positive outcomes for patients.

How ketamine metabolite (2R,6R)-hydroxynorketamine effectively reduces anxiety-like behaviors associated with morphine withdrawal in mice by modulating neuronal excitability and potassium channel activity in the brain.

A single low dose of esketamine administered right after childbirth shows promise for postpartum depression, showing it could be a viable treatment option for new mothers showing signs of prenatal depression.

Ketamine shows better faster relief with fewer adverse events.

The retrospective study analyzed 68 treatment sessions involving 41 patients aged 5-21 years, predominantly girls with chronic migraine without aura. Patients were administered a median dose of 0.25 mg/kg/hr of IV ketamine over a median duration of 3 days.

Chronic pain and depression diagnoses are skyrocketing. There is an urgent need for more effective treatments. Ketamine was recently established to alleviate pain and depression, but many gaps remain in the scientific literature.